Browse by author
Lookup NU author(s): Dr Gendie Lash
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Tumour hypoxia is associated with resistance to therapy and with increased invasion and metastatic potential. Recent studies in our laboratory have shown that the hypoxic up-regulation of tumour cell invasiveness and chemoresistance is in part due to reduced nitric oxide (NO) signaling. Using B16F10 murine melanoma cells, we demonstrate here that the increased metastatic potential associated with exposure to hypoxia is mediated by a reduction in cGMP-dependent NO-signaling. Pre-incubation of B16F10 cells in hypoxia (1% vs. 20% O2) for 12 hr increased lung colonization ability by over 4-fold. This effect of hypoxia on metastasis was inhibited by co-incubation with low concentrations of the NO-mimetic drugs glyceryl trinitrate (GTN) and diethylenetriamine NO adduct (DETA/NO). In a manner similar to hypoxia, pharmacological inhibition of NO synthesis resulted in a significant increase in lung nodule formation, an effect that was prevented by co-incubation with GTN. An important NO-signaling pathway involves the activation of soluble guanylyl cyclase and the consequential generation of cGMP. Culture in the presence of a non-hydrolysable cGMP analogue (8-Br-cGMP) abrogated the hypoxia-induced lung nodule formation, suggesting that the effects of NO on metastasis are mediated via a cGMP-dependent pathway. These findings suggest that a novel mechanism whereby hypoxia regulates metastatic potential involves a downstream inhibition of cGMP-dependent NO signaling. © 2003 Wiley-Liss, Inc.
Author(s): Postovit L-M, Adams MA, Lash GE, Heaton JPW, Graham CH
Publication type: Article
Publication status: Published
Journal: International Journal of Cancer
Year: 2004
Volume: 108
Issue: 1
Pages: 47-53
ISSN (print): 0020-7136
ISSN (electronic): 1097-0215
Publisher: John Wiley & Sons, Inc.
URL: http://dx.doi.org/10.1002/ijc.11556
DOI: 10.1002/ijc.11556
PubMed id: 14618614
Altmetrics provided by Altmetric
